A protein that helps protect the brain could offer scientists a promising new way to fight Alzheimer’s disease and other forms of dementia. Researchers have found that increasing levels of this protein can reduce the buildup of toxic tangles associated with brain injury, while helping to preserve the connections that allow nerve cells to communicate.
The results, published in Scientific advances by scientists at Sanford Burnham Prebys, suggest that strengthening the brain’s protective mechanisms could eventually lead to new treatments for neurodegenerative diseases. In experiments on mice, researchers found that increasing the protein reduced several damaging changes associated with Alzheimer’s disease, including brain shrinkage and accumulation of abnormal tau proteins.
The discovery is particularly important because the Tau protein plays a critical role in maintaining the function of healthy brain cells. Under normal conditions, tau proteins help stabilize microtubules, tiny structures that provide internal support to neurons and help maintain the complex networks of the nervous system.
However, in Alzheimer’s disease and several related disorders, tau proteins can become abnormal and stick together, forming harmful clumps called tau tangles. These tangles disrupt the normal function of nerve cells and are associated with cognitive decline and neuronal death. Diseases characterized by abnormal accumulation of tau are collectively called tauopathies.
A protective protein with a surprising role in Alzheimer’s disease
The researchers studied a protein called sorting repeat-related receptor A (SORLA), which has already attracted the attention of scientists for its potential role in protecting the brain against Alzheimer’s disease.
Previous studies have shown that SORLA may help limit the production and accumulation of beta-amyloid, another protein closely associated with Alzheimer’s disease. Beta-amyloid can build up in plaques in the brain, making it one of the main pathological hallmarks of the disease, alongside tau tangles.
“Over the last 15 or 20 years, considerable data have come out of our lab and other groups showing that SORLA can suppress one of the hallmarks of Alzheimer’s disease – the generation and accumulation of beta-amyloid,” said Timothy Huang, PhD, assistant professor at the Sanford Burnham Prebys Center for Neurological Diseases.
“However, very little was known about whether SORLA affected the tau tangles reflected on the other side of the coin in Alzheimer’s disease.”
To study this question, scientists developed a mouse model by breeding animals engineered to produce additional human SORLA with mice developing tau tangles, brain atrophy, and cognitive impairments. This allowed them to examine whether higher levels of SORLA could reduce tau accumulation and protect against the damage it causes.
Stimulating SORLA Reduces Toxic Tau and Brain Shrinkage
Results revealed that supplemental SORLA provided protection against several processes contributing to tau tangles and the progression of neurodegenerative diseases.
One important effect involved a process called hyperphosphorylation. This happens when too many phosphate groups attach to tau proteins, changing their behavior and contributing to the development of harmful tangles. Higher levels of SORLA reduced this abnormal change.
The protein also limited the ability of misfolded tau to act as “seeds” that encourage other tau proteins to clump together. This seeding process can help toxic aggregates of tau multiply and spread their harmful effects.
Beyond reducing tau abnormalities, SORLA helped preserve synapses, the specialized connections through which neurons communicate. It also protects synaptic plasticity, the brain’s ability to strengthen or modify these connections, essential for learning, memory and normal cognitive function.
“When you upregulate SORLA, you can suppress the negative effects seen in tauopathies,” said Huijie Huang, PhD, a researcher in the Huang lab at Sanford Burnham Prebys and senior author of the study.
“We found that there was less brain atrophy and less tau accumulation, which was very exciting to see.”
Removal of protein worsens brain damage
After observing the benefits of increasing SORLA, the researchers looked at what would happen if the protein was missing completely.
SORLA is produced using instructions encoded by a gene called Sorl1. Some people carry mutations that interfere with the functioning of this gene, potentially disrupting the production or activity of the protective protein.
To study the consequences, the team studied genetically modified mice lacking Sorl1 and therefore could not produce SORLA.
The results contrasted sharply with those observed in mice carrying extra copies of the protein. Instead of protecting against tau-related damage, the absence of SORLA made the harmful effects more severe.
“The opposite turned out to be true when we removed the ability to produce SORLA proteins,” said Tim Huang, senior and corresponding author of the manuscript. “A lack of SORLA exacerbated the adverse effects observed in tauopathies.”
These contrasting results provided further evidence that SORLA plays an important protective role in the brain and may influence the severity of Tau-related disease progression.
New clue could lead to treatments for Alzheimer’s disease
To understand why changing SORLA levels had such different effects, the researchers looked at the molecular activity of individual brain cells and surrounding tissues.
They combined advanced sequencing methods for measuring protein levels and gene activity in individual cells with techniques for mapping the location of RNA and proteins in brain tissue. This detailed approach revealed how SORLA influences the biological processes involved in neurodegeneration.
The analysis showed that increasing SORLA helped prevent detrimental changes in protein production at synapses while suppressing other mechanisms associated with tauopathy progression.
The researchers also found that higher levels of SORLA reduced abnormal gene activity in glial cells. These cells perform several essential functions in the nervous system, including supporting, maintaining, and protecting neurons. Changes in glial cell activity may contribute to the progression of neurodegenerative diseases.
One finding was particularly intriguing because it pointed to a potential target for existing drugs.
“A particularly remarkable finding that we can build on is the upregulation of a member of the plexin-B receptor family in the absence of SORLA,” said Huijie Huang.
Plexin-B receptors are proteins involved in cellular signaling, helping cells respond to information from their environment. The increased activity of a receptor in this family when SORLA was absent suggests that this signaling pathway may be involved in some of the damaging changes associated with tau disorders.
Importantly, there are already drugs that can target this family of receptors, suggesting that scientists could study whether they might be useful against Tau-related dementia.
“There are unique drugs that can target this class of receptors that we could apply to Tau-related dementia disorders,” said Tim Huang. “A potential future direction is to repurpose these drugs to target overactivation of glial cells and perhaps reverse certain phenotypes of tauopathies.”
The next step towards human Alzheimer’s disease research
Although the results are encouraging, the protective effects have been demonstrated in mice and further research is needed to determine how these mechanisms work in humans.
The team now hopes to study how each type of brain cell responds when SORLA levels increase or decrease. One planned approach is to transplant human neurons or glial cells into mouse brains, allowing researchers to examine the effects of different SORLA mutations in a living disease-affected brain.
“Mouse cells and human cells are different,” said Tim Huang. “Because we are studying human disease, it is more informative if we can observe the modulation and dysfunction of SORLA in the context of a human cell inside a diseased brain environment.”
These experiments could help clarify how SORLA protects neurons from toxic tau accumulation and why disruptions in its function worsen neurodegeneration.
Ultimately, researchers hope that a deeper understanding of this protective protein will reveal new treatment strategies, either by enhancing SORLA’s activity or by repurposing existing drugs to interfere with damaging cellular pathways. Such approaches could potentially offer new ways to combat Alzheimer’s disease and other forms of dementia caused by toxic tau tangles.
The study was supported by the National Institutes of Health, the National Cancer Institute, and the National Institute on Aging.
Gn Health
